KORU Medical Systems, Inc. (NASDAQ: KRMD) reported financial results for the third quarter ended September 30, 2026, announcing positive net income for the second consecutive quarter. The company reported total net revenues of $11.6 million for the three-month period, representing an 11.2% increase compared to the same period in the prior year. Year-to-date net revenues through September 30, 2026, totaled $35.4 million, reflecting 17% growth.
Gross profit for the third quarter increased 20.5% to $7.5 million, with gross margins improving to 65.2% from 60.2% in the prior year. This improvement was driven by lower manufacturing costs, higher selling prices, and tariff-related rebates. Net income for the quarter was $0.2 million, or $0.00 per diluted share, compared to a net loss of $0.8 million, or ($0.02) per diluted share, in the prior year period. Adjusted EBITDA for the quarter was $1.3 million, or $0.02 per adjusted diluted share, up from $0.1 million in the prior year.
Domestic core revenues increased 31.6% to $8.1 million, primarily due to higher pump and consumable volumes and new patient starts. International core revenues decreased 16.5% to $3.1 million, attributed to a higher prior-year comparison base and inventory adjustments by distributors. Pharma services and clinical trials revenues decreased 27.4% to $0.4 million.
KORU Medical updated its full-year 2026 revenue guidance to $48.0 million to $48.5 million, representing year-over-year growth of 17% to 18%. The company also raised its full-year 2026 gross margin guidance to between 63% and 64% and expects year-end cash balances to exceed $8.0 million.
